CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Conditions
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphocytic Leukaemia Refractory
- Non-Hodgkin's Lymphoma, Relapsed
- Non-Hodgkin's Lymphoma Refractory
Interventions
- DRUG: CD19/BCMA Targeted CAR T-cells and dasatinib
- DRUG: CD19/BCMA Targeted CAR T-cells
Sponsor
Zhejiang University
Collaborators